A damaged gut microbiome significantly increases the risk of dangerous drug-resistant CRE infections, especially in cancer patients, according to a 2026 Gram Research analysis of current evidence. When cancer treatment or antibiotics disrupt the protective community of gut bacteria, harmful CRE bacteria can colonize the intestines and spread to the bloodstream. Restoring gut health through microbiome-targeted interventions like fecal microbiota transplantation shows promise for preventing these life-threatening infections, though more research is needed to establish standardized, effective prevention strategies.
According to Gram Research analysis, a new review examines how harmful drug-resistant bacteria called CRE colonize the gut and cause serious infections, especially in cancer patients. The research shows that a healthy gut microbiome—the trillions of bacteria living in your digestive system—acts like a protective shield against these dangerous pathogens. When cancer treatment or antibiotics damage this protective barrier, CRE bacteria can take over and spread throughout the body. Scientists are exploring new ways to restore gut health, including fecal microbiota transplantation and other microbiome-targeted treatments, to prevent these infections before they start.
Key Statistics
A 2026 narrative review in Frontiers in Cellular and Infection Microbiology found that intestinal colonization with carbapenem-resistant Enterobacterales (CRE) is the key precursor to invasive infections in patients with hematological malignancies, with gut dysbiosis playing a central role in enabling bacterial persistence.
According to research reviewed by Gram, fecal microbiota transplantation currently represents the most promising microbiome-based intervention for preventing CRE infections, though available clinical evidence remains heterogeneous and largely derived from small studies requiring larger multicenter trials.
A 2026 review identified that loss of colonization resistance—the healthy microbiome’s ability to prevent harmful bacteria from establishing themselves—occurs through reduced bacterial diversity, depletion of protective anaerobic bacteria, intestinal barrier dysfunction, and immune dysregulation.
The 2026 analysis found that while selective digestive decontamination, probiotics, prebiotics, bacteriophage therapy, and CRISPR-based technologies show theoretical promise for CRE decolonization, durable and standardized decolonization strategies have yet to be established in clinical practice.
The Quick Take
- What they studied: How a damaged gut microbiome (the community of bacteria in your digestive system) allows dangerous drug-resistant bacteria called CRE to colonize and cause life-threatening infections, particularly in patients with blood cancers
- Who participated: This is a narrative review that analyzed existing research on CRE infections and microbiome health, with special focus on patients with hematological malignancies (blood cancers)
- Key finding: A healthy, diverse gut microbiome protects against CRE colonization and infection. When this protective barrier breaks down due to cancer treatment or antibiotics, CRE bacteria can multiply and spread, causing serious infections
- What it means for you: If you have a blood cancer or are at high risk for CRE infections, protecting your gut bacteria through targeted interventions may help prevent dangerous infections. However, most of these preventive strategies are still being studied and should only be used under medical supervision
The Research Details
This is a narrative review, which means researchers examined and summarized existing scientific literature on carbapenem-resistant Enterobacterales (CRE) infections and gut microbiome health. Rather than conducting a new experiment, the authors collected findings from multiple studies to identify patterns and draw conclusions about how gut bacteria influence CRE infection risk.
The review focused specifically on patients with hematological malignancies—cancers of the blood and bone marrow—because these patients face the highest risk of CRE infections. The researchers examined how the gut microbiome changes during cancer treatment, how these changes allow CRE bacteria to colonize the intestines, and what strategies might prevent progression from colonization to active infection.
The authors evaluated both traditional approaches (like selective digestive decontamination with antibiotics) and newer microbiome-based interventions (like fecal microbiota transplantation, probiotics, and bacteriophage therapy) to determine which show the most promise for preventing CRE infections.
Understanding the connection between gut microbiome health and CRE infection risk is crucial because current antibiotic treatments are becoming less effective. By identifying how a damaged microbiome allows dangerous bacteria to take hold, researchers can develop prevention strategies that work with the body’s natural defenses rather than relying solely on antibiotics. This is especially important for cancer patients, whose immune systems are already compromised by their disease and treatment.
As a narrative review, this study synthesizes existing research rather than generating new experimental data. The strength of the conclusions depends on the quality and consistency of the studies reviewed. The authors acknowledge that most evidence for microbiome-based interventions comes from small studies with varying methods, which limits how confident we can be about recommendations. The review’s value lies in identifying gaps in current knowledge and highlighting the need for larger, well-designed clinical trials.
What the Results Show
The review reveals that CRE colonization of the gut is the primary stepping stone to serious infection, particularly in cancer patients. When the gut microbiome becomes disrupted—a condition called dysbiosis—several harmful changes occur simultaneously: the diversity of beneficial bacteria decreases, protective anaerobic bacteria (bacteria that don’t need oxygen) are depleted, the intestinal barrier weakens, and immune function becomes impaired. These changes create an ideal environment for CRE bacteria to multiply and establish themselves in the gut.
Once CRE bacteria colonize the gut, they can breach the weakened intestinal barrier and enter the bloodstream, causing life-threatening infections. This progression is particularly dangerous in patients with blood cancers because their immune systems are already compromised by their disease and chemotherapy treatments. The review emphasizes that preventing colonization is far more effective than trying to treat active infections, since CRE bacteria are resistant to most antibiotics.
The research identifies a critical concept called ‘colonization resistance’—the ability of a healthy microbiome to prevent harmful bacteria from establishing themselves. When this resistance is lost due to dysbiosis, CRE bacteria can flourish unchecked. Restoring colonization resistance through microbiome-targeted interventions has emerged as the most promising prevention strategy.
The review examines several emerging treatment approaches: Fecal microbiota transplantation (FMT), which transfers healthy bacteria from a donor to restore the patient’s microbiome, currently shows the most promise but requires more rigorous testing. Probiotics and prebiotics (which feed beneficial bacteria) have theoretical benefits but limited clinical evidence in CRE prevention. Bacteriophage therapy (using viruses that kill specific bacteria) and CRISPR-based technologies (genetic tools that can target harmful bacteria) represent exciting future possibilities but remain largely experimental. Selective digestive decontamination, a traditional approach using antibiotics to eliminate harmful bacteria, can work but may contribute to antibiotic resistance over time.
This review builds on growing recognition that antibiotic resistance requires new prevention strategies beyond traditional antibiotics. Previous research established that gut colonization precedes infection, but this review synthesizes newer evidence showing exactly how microbiome damage enables CRE persistence. The emphasis on microbiome-targeted interventions represents a shift from purely antimicrobial approaches to ecological restoration—essentially rebuilding the gut’s natural defenses rather than just killing bacteria.
The review acknowledges several important limitations: Most clinical evidence for microbiome-based interventions comes from small studies with inconsistent methods, making it difficult to draw definitive conclusions. FMT, while promising, lacks standardized protocols and long-term safety data. Most research focuses on hospitalized patients, so findings may not apply to outpatient settings. The review is based on existing literature rather than new data, so conclusions depend on the quality of published studies. Finally, many emerging therapies like bacteriophage and CRISPR approaches remain experimental with limited human testing.
The Bottom Line
For patients with blood cancers or high CRE infection risk: Work with your medical team to minimize unnecessary antibiotic use, which damages protective gut bacteria. Discuss whether microbiome-targeted interventions like probiotics or FMT might be appropriate for your situation (moderate confidence—evidence is emerging). Maintain overall health through diet and lifestyle to support gut bacteria diversity. For healthcare providers: Consider screening high-risk patients for CRE colonization and implementing microbiome-protective strategies. Participate in clinical trials testing new decolonization approaches (moderate confidence—more research needed).
Patients with hematological malignancies (blood cancers) should prioritize this information, as they face the highest risk. Healthcare providers treating cancer patients, immunocompromised individuals, or hospitalized patients should understand these concepts. People taking prolonged antibiotics should be aware of microbiome impacts. General population should understand that gut health supports infection prevention, though CRE risk is primarily a concern for high-risk groups.
Preventing CRE colonization is an ongoing process, not a quick fix. Microbiome restoration through interventions like FMT may show benefits within weeks to months, but long-term durability remains unclear. Cancer patients should implement protective strategies throughout treatment and recovery. Benefits of probiotics or dietary changes typically take 4-8 weeks to manifest. Realistic expectations: These approaches reduce infection risk but don’t guarantee prevention.
Frequently Asked Questions
What are carbapenem-resistant Enterobacterales and why are they dangerous?
CRE are bacteria resistant to most antibiotics, making infections extremely difficult to treat. They’re particularly dangerous in cancer patients whose immune systems are already weakened. CRE colonize the gut first, then can spread to the bloodstream causing life-threatening infections that antibiotics can’t effectively combat.
How does chemotherapy affect gut bacteria and infection risk?
Cancer treatment damages the protective community of gut bacteria (microbiome), reducing beneficial bacteria diversity and weakening the intestinal barrier. This creates conditions where harmful CRE bacteria can multiply unchecked and breach into the bloodstream, causing serious infections in already-compromised immune systems.
Is fecal microbiota transplantation proven to prevent CRE infections?
FMT shows the most promise among microbiome-based interventions for preventing CRE infections, but current evidence comes from small studies with varying methods. Larger, well-designed clinical trials are needed to confirm effectiveness and establish standardized protocols before widespread clinical use.
Can probiotics prevent drug-resistant bacterial infections?
Probiotics have theoretical benefits for restoring gut bacteria, but clinical evidence specifically for CRE prevention remains limited. While generally safe, probiotics alone are unlikely to be sufficient—they work best as part of comprehensive microbiome-protective strategies under medical supervision.
What can cancer patients do to protect their gut bacteria during treatment?
Minimize unnecessary antibiotics when possible, maintain adequate dietary fiber to feed beneficial bacteria, discuss microbiome-protective strategies with your medical team, and avoid practices that further damage gut bacteria. Work with healthcare providers to monitor gut health throughout cancer treatment and recovery.
Want to Apply This Research?
- Log antibiotic use and timing, track gastrointestinal symptoms (bloating, diarrhea, constipation) weekly, and record any fever or infection signs. For cancer patients: correlate symptom changes with chemotherapy cycles and microbiome interventions.
- If prescribed probiotics or prebiotics, set daily reminders to take them consistently. Track dietary fiber intake (aim for 25-30g daily) to feed beneficial bacteria. Log any microbiome-targeted interventions (FMT, dietary changes) and monitor subsequent health outcomes.
- Establish a baseline of gut health symptoms before cancer treatment begins. Monitor changes monthly during treatment. If microbiome interventions are used, track infection rates, antibiotic courses needed, and gastrointestinal symptoms for 6-12 months to assess effectiveness. Share data with healthcare providers to inform personalized prevention strategies.
This article summarizes a narrative review of existing research and should not be considered medical advice. CRE infections and microbiome-targeted interventions are complex medical topics that require individualized assessment by qualified healthcare providers. If you have a blood cancer diagnosis, are at risk for CRE infections, or are considering microbiome-based interventions like fecal microbiota transplantation, consult with your oncologist or infectious disease specialist before making any treatment decisions. The interventions discussed, particularly FMT and emerging therapies, are still being studied and may not be appropriate or available for all patients. This information is current as of 2026 and reflects the state of research at that time.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
